問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Digestive System Department

Division of General Internal Medicine

更新時間：2023-09-19

高嘉宏Kao, Jia-Horng
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 9 個月

Recruiting Trial

31Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

高嘉宏

List

106Cases

2014-12-01 - 2016-12-31

Others

A Phase IIB-III, open-label, randomized, comparative study to assess the efficacy of ABX203 to maintain control of Hepatitis B disease after cessation of treatment with nucleos(t)ide analogs in adult HBeAg negative patients with chronic Hepatitis B in the Asia Pacific region

  • Condition/Disease

    chronic Hepatitis B

  • Test Drug

    ABX203

Participate Sites
12Sites

Terminated12Sites

2011-02-01 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2017-01-01 - 2018-12-31

Phase I

A Phase 1, double-blind, randomized, placebo-controlled, first-in-human study of orally administered JNJ-56136379 to evaluate safety, tolerability and pharmacokinetics after single ascending doses and one multiple dose regimen in healthy subjects (Part I), and after multiple dose regimens in subjects with chronic hepatitis B (Part II)

  • Condition/Disease

    Chronic hepatitis B

  • Test Drug

    JNJ-56136379

Participate Sites
5Sites

Terminated5Sites

2015-03-15 - 2017-05-30

Phase II

: A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 or Genotype 3 Infection (SURVEYOR-II)

  • Condition/Disease

    Chronic Hepatitis C Virus (HCV)

  • Test Drug

    ABT-530, ABT-493

Participate Sites
6Sites

Terminated5Sites

2016-03-14 - 2017-09-07

Phase III

A Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Subjects with Chronic Hepatitis C Virus Genotype 1 – 6 Infection (MAGELLAN-2)

  • Condition/Disease

    Post-Liver or Post-Renal Transplant Subjects with Chronic Hepatitis C Virus Genotype 1 – 6 Infection

  • Test Drug

    ABT-493/ABT-530

Participate Sites
2Sites

Terminated2Sites

朱啟仁
Taipei Veterans General Hospital

Digestive System Department

2015-10-26 - 2017-05-30

Phase III

A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus Genotype 1 Infection (ENDURANCE-1)

  • Condition/Disease

    Chronic Hepatitis C Virus Genotype 1 Infection

  • Test Drug

    ABT-493/ABT-530

Participate Sites
9Sites

Terminated8Sites

彭成元
China Medical University Hospital-Taipei

未分科

朱啟仁
Taipei Veterans General Hospital

Digestive System Department

2015-09-16 - 2017-06-30

Phase III

An Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered with Ribavirin (RBV) in Treatment-Naïve and Treatment-Experienced Asian Adults with Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis

  • Condition/Disease

    Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis

  • Test Drug

    ABT-450/Ritonavir/ABT-267, ABT-333, Ribavirin

Participate Sites
6Sites

Terminated5Sites

朱啟仁
Taipei Veterans General Hospital

Digestive System Department

彭成元
China Medical University Hospital-Taipei

未分科

2009-10-31 - 2012-10-20

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

2020-05-01 - 2025-03-31

Phase II

A Phase II, Randomised, Adaptive, Open-Label Platform Trial To Evaluate Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B

  • Condition/Disease

    Chronic Hepatitis B Infection

  • Test Drug

    RO7049389、RO7020531、Vemlidy韋立得、Viread 惠立妥、Baraclude 貝樂克

Participate Sites
6Sites

Recruiting6Sites

2023-01-05 - 2026-12-31

Phase III

Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment With Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B Virus (B-Well 2)

  • Condition/Disease

    Chronic Hepatitis B

  • Test Drug

    GSK3228836/Bepirovirsen

Participate Sites
4Sites

Terminated4Sites

1 3 4 5 6 7 11
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB